

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
-------------------------	----------------

<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
------------------------------	------------

<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Adenosine Therapeutics, LLC	08/20/2008

<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PGxHealth, LLC
<b>Street Address:</b>	One Gateway Center, Suite 702
<b>City:</b>	Newton
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02458

**PROPERTY NUMBERS Total: 51**

Property Type	Number
Application Number:	10923592
Application Number:	11956876
Application Number:	12049801
Application Number:	11803312
Application Number:	60559159
Application Number:	11097251
Application Number:	60794843
Application Number:	60747625
Application Number:	11804165
Application Number:	60805030
Application Number:	60805564
Application Number:	11811823
Application Number:	60656105
Application Number:	11362393
Application Number:	60656087

**CH \$2040.00 10923592**

Application Number:	11362387
Application Number:	60656104
Application Number:	11362390
Application Number:	60656086
Application Number:	11362392
Application Number:	60807545
Application Number:	11879133
Application Number:	60711422
Application Number:	11510632
Application Number:	60824316
Application Number:	11897678
Application Number:	60925736
Application Number:	12102185
Application Number:	61015303
Application Number:	61019912
Application Number:	61014134
Application Number:	61046568
Application Number:	60885489
Application Number:	12014949
Application Number:	61075096
Application Number:	11975080
Application Number:	60471643
Application Number:	10848403
PCT Number:	US0427133
PCT Number:	US0511078
PCT Number:	US0712043
PCT Number:	US0713849
PCT Number:	US0606748
PCT Number:	US0606745
PCT Number:	US0606838
PCT Number:	US0606746
PCT Number:	US0716164
PCT Number:	US0719266
PCT Number:	US0860304
PCT Number:	US0800549

PCT Number:

US0415783

**CORRESPONDENCE DATA**

Fax Number: (617)965-0445

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 617-527-9933

Email: KPorzelt@CLDA.com

Correspondent Name: Kathleen Porzelt

Address Line 1: One Gateway Center, Suite 702

Address Line 4: Newton, MASSACHUSETTS 02458

**NAME OF SUBMITTER:**

David H Vance

**Total Attachments: 9**

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page1.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page2.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page3.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page4.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page5.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page6.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page7.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page8.tif

source=ATL-PGxHealth\_Asset\_Assignment-redacted#page9.tif

## PATENT ASSIGNMENT AGREEMENT

WHEREAS, ADENOSINE THERAPEUTICS, L.L.C., a Virginia limited liability company (hereinafter referred to as “Assignor”) has agreed that it will assign to Assignee (defined below) all of its right, title and interest in and to all of the patents and patent applications listed or described in Schedule 1 attached hereto and incorporated herein by reference; and

WHEREAS, PGX HEALTH, LLC, a Delaware limited liability company (hereinafter referred to as “Assignee”) and a wholly-owned subsidiary of Clinical Data, Inc., a Delaware Corporation, is desirous of acquiring all rights, title, and interest in and under the Intellectual Property (as defined below).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors and assigns all of its right, title and interest to those patents and applications identified as such in Schedule 1 hereto, and (i) all U.S. and foreign patents and patent applications that claim priority to such identified patents and applications and all U.S. and foreign patents and applications to which such identified patents and applications relate or claim priority, directly or indirectly, (ii) any provisionals, continuations, continuations-in-part, divisionals, reissue applications, re-examinations, substitutions, extensions, foreign counterparts, Patent Cooperation Treaty applications, or derivatives of any of the foregoing, both foreign and domestic, which have or may be filed, (iii) all patents (including, but not limited to reissues and re-examinations) which may be granted on the applications set forth in (i) and (ii) above, and (iv) all patentable inventions, in the U.S. and every foreign country, described or embodied in any of the foregoing, (the “Intellectual Property”) and does hereby authorize and request the Commissioner of Patents to issue U.S. patents to the above-mentioned Assignee in accordance with the terms of this assignment document. Such full and exclusive rights shall include, without limitation, the right to sue upon and otherwise enforce the Intellectual Property and to recover all past damages and other potential relief arising from infringement of the Intellectual Property assigned by this agreement.

ASSIGNOR HEREBY AUTHORIZES Assignee and its attorney of record to insert on this assignment document, including Schedule 1, any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office and/or any foreign patent office for recordation of this document and Assignor hereby authorizes and requests the United States Patent and Trademarks Office to issue said Letter Patents in accordance with this agreement.

UPON SAID CONSIDERATION, Assignor conveys to Assignee the right to make application in its own behalf for protection of the Intellectual Property in the U.S. and countries foreign to the U.S. and to claim under the Patent Cooperation Treaty, the International Convention and/or other international arrangement for any such application the date of any earlier U.S. application (or any other application on the invention) to gain priority with respect to other applications.

IN WITNESS WHEREOF, Assignor has caused one of its authorized representatives to hereunder set his hand on the date shown below and Assignee has caused one of its officers to hereunder set his hand on the date shown below to signify its acceptance of this assignment.

[Signature page follows]

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment Agreement to be signed by its duly authorized officer as of August 20, 2008.

**ASSIGNOR**

**ADENOSINE THERAPEUTICS, L.L.C.**

By: [Signature]  
Name: Robert S. Capon  
Title: Chief Executive Officer

**ASSIGNEE**

**PGx HEALTH, LLC**

By: Cogenics, Inc. (its Sole Member)


By: \_\_\_\_\_  
Name: Caesar J. Belbel  
Title: Executive Vice President, Chief  
Legal Officer and Secretary

Commonwealth  
State of Virginia )  
City of Charlottesville ) ss.  
County of Charlottesville )

On August 20th, 2008, before me, Joseph Milton, Notary Public, personally appeared Robert S. Capon, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

[Signature] Notary ID 7101431  
Signature of Notary Public



My Commission Expires: June 30, 2011

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment Agreement to be signed by its duly authorized officer as of August \_\_\_\_, 2008.


**ASSIGNOR**

**ADENOSINE THERAPEUTICS, L.L.C.**

By: \_\_\_\_\_  
Name: Robert S. Capon  
Title: Chief Executive Officer

**ASSIGNEE**

**PGX HEALTH, LLC**

By: Cogenics, Inc. (its Sole Member)  
By:   
Name: Caesar J. Belbel  
Title: Executive Vice President, Chief  
Legal Officer and Secretary

State of Massachusetts )  
County of Middlesex ) ss.

On August 7, 2008, before me, Kathleen Porzelt, Notary Public, personally appeared Caesar J. Belbel, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Kathleen Porzelt  
Signature of Notary Public

Place Notary Seal Above

My Commission Expires: Feb. 7, 2014

Seller Patents handled by Williams Mullen

WM File No.	Seller File No.	City	Case Type	Status	Short Title	App. No. App Date
<del>029514.0045</del>	<del>ATL-002-AB</del>	<del>AB</del>	<del>XP2</del>	<del>BEN</del>	<del>Substituted 8 - Heteroaryl Xanthines Pharmaceutical Compositions...</del>	<del>P040103059 08/25/04</del>
<del>029514.0059</del>	<del>ATL-002-AU</del>	<del>AU</del>	<del>XP2</del>	<del>BEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>2004268964 03/02/06</del>
<del>029514.0067</del>	<del>ATL-002-BR</del>	<del>BR</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>P10443992-4 02/24/06</del>
<del>029514.0068</del>	<del>ATL-002-GA</del>	<del>CA</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>2506558 02/22/06</del>
<del>029514.0043</del>	<del>ATL-002-CN</del>	<del>CN</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>200480034455-4 04/24/06</del>
<del>029514.0044</del>	<del>ATL-002-EP</del>	<del>EP</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>EP04784759-9 02/14/06</del>
<del>029514.0066</del>	<del>ATL-002-HK</del>	<del>HK</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>7103594.7 4/8/07</del>
<del>029514.0040</del>	<del>ATL-002-IL</del>	<del>IL</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>172723 02/14/06</del>
<del>029514.0044</del>	<del>ATL-002-IN</del>	<del>IN</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>10144CHENID/2006 02/24/06</del>
<del>029514.0042</del>	<del>ATL-002-JP</del>	<del>JP</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>2006-524755 02/27/06</del>
<del>029514.0084</del>	<del>ATL-002-KR</del>	<del>KR</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>2006-7002776 02/24/06</del>
<del>029514.0095</del>	<del>ATL-002-MX</del>	<del>MX</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>Patent 2006/0002283 02/24/06</del>
<del>029514.0046</del>	<del>ATL-002-NZ</del>	<del>NZ</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>545745 02/09/06</del>
<del>029514.0045</del>	<del>ATL-002-PCT</del>	<del>WO</del>	<del>PCT</del>	<del>EXP</del>	<del>Substituted 8 Heteroaryl Xanthines</del>	<del>US2004/027133 08/20/04</del>
<del>029514.0036</del>	<del>ATL-002-RU</del>	<del>RU</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>2006109474 03/24/06</del>

PATENT

REEL: 022075 FRAME: 0740

WM File No.	Seller File No.	Ctry	Case Type	Status	Short Title	App. No. App Date
<del>029514.0033</del>	<del>ATL-002-GG</del>	<del>SG</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>20060100572</del> <del>02/15/09</del>
<del>029514.0034</del>	<del>ATL-002-TW</del>	<del>TW</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>09025400</del> <del>08/26/04</del>
029514.0048	ATL-002-US	US	NAT	REG	Utility - Substituted 8 - Heteroaryl Xanthines	10/923,592 08/20/04
029514.0100	ATL-002-US2	US	CONT	PEN	Substituted 8-Heteroaryl Xanthines	11/956,876 12/14/2007
<del>029514.0047</del>	<del>ATL-002-ZA</del>	<del>ZA</del>	<del>XP2</del>	<del>PEN</del>	<del>Substituted 8 - Heteroaryl Xanthines</del>	<del>20060999</del> <del>02/29/09</del>
<del>029514.0025</del>	<del>ATL-003-AL</del>	<del>AL</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>2005294440</del> <del>09/25/09</del>
<del>029514.0024</del>	<del>ATL-003-CA</del>	<del>CA</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>2563123</del> <del>09/29/09</del>
<del>029514.0022</del>	<del>ATL-003-CN</del>	<del>CN</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>2005800475402</del> <del>11/29/06</del>
029514.0110	ATL-003-CNT2	US	CONT	PEN	Selective Antagonists A2A Receptors	12/049,801 3/17/08
029514.0075	ATL-003-CON	US	CNT	ABD	Selective Antagonists A2A Adenosine Receptors	11/803,312 5/14/07
<del>029514.0023</del>	<del>ATL-003-EP</del>	<del>EP</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>57404030</del> <del>11/17/06</del>
<del>029514.0068</del>	<del>ATL-003-HK</del>	<del>HK</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>071969477</del> <del>5/28/07</del>
<del>029514.0021</del>	<del>ATL-003-IL</del>	<del>IL</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>4789965</del> <del>09/28/06</del>
<del>029514.0078</del>	<del>ATL-003-IN</del>	<del>IN</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>00129109</del>
<del>029514.0020</del>	<del>ATL-003-JP</del>	<del>JP</del>	<del>XP2</del>	<del>PEN</del>	<del>Selective Antagonists A2A Adenosine Receptors</del>	<del>2007506609</del> <del>11/02/06</del>
029514.0019	ATL-003-PCT	WO	PCT	EXP	Selective Antagonists A2A Adenosine Receptors	US2005/011078 04/04/05
029514.0049	ATL-003-PR	US	PRO	CLD	Provisional 1 - Selective Antagonists A2A Adenosine Receptors	60/559,159 04/02/04

PATENT

REEL: 022075 FRAME: 0741



WM File No.	Seller File No.	Ctry	Case Type	Status	Short Title	App. No. App Date
029514.0051	ATL-003-US	US	NAT	REG	Utility - Selective Antagonists A2A Adenosine Receptors	11/097,251 04/04/05
*029514.0077	ATL-004-PCT	WO	PCT	PEN	Substituted Aryl/piperidinyalkyladenosines as A2A Agonist	US2007/012043 5/18/07
029514.0057	ATL-004-PR	US	PRO	CLD	Provisional 1 - Substituted Aryl Piperidinyalkyladenosines as A2AR Agonists	60/794,843 04/26/06
029514.0058	ATL-004-PR1	US	PRO	CLD	Provisional 2 - Substituted Aryl Piperidinyalkyladenosines as A2AR Agonists	60/747,625 05/18/06
029514.0076	ATL-004-US	US	NAT	PEN	Substituted Aryl/piperidinyalkyladenosines as A2A Agonist	11/804,165 5/14/07
029514.0091	ATL-005-PCT	WO	PCT	PEN	Substituted 8 Heteroaryl Xanthines	US2007/013849 6/13/07
029514.0046	ATL-005-PR	US	PRO	CLD	Provisional 1 - Substituted 8 - Heteroaryl Xanthines	60/805,030 06/16/06
029514.0047	ATL-005-PR1	US	PRO	CLD	Provisional 2 - Substituted 8 - Heteroaryl Xanthines	60/805,564 06/22/06
029514.0090	ATL-005-US	US	NAT	PEN	Substituted 8 Heteroaryl Xanthines	11/811,823 6/12/2007
029514.0027	ATL-006-PCT	WO	PCT	PEN	Pyrazol YL Substituted Xanthines	US2006/06748 02/27/06
029514.0065	ATL-006-PR	US	PRO	CLD	Provisional - Pyrazolyl Substituted Xanthines	60/656,105 02/25/05
029514.0066	ATL-006-US	US	NAT	PEN	Utility - Pyrazolyl Substituted Xanthines	11/362,393 02/27/06
029514.0028	ATL-007-PCT	WO	PCT	PEN	Pyridyl Substituted Xanthines	US2006/006745 02/27/06
029514.0055	ATL-007-PR	US	PRO	CLD	Provisional - Pyridyl Substituted Xanthines	60/656,087 02/25/05
029514.0056	ATL-007-US	US	NAT	PEN	Utility - Pyridyl Substituted Xanthines	11/362,387 02/27/06
029514.0029	ATL-008-PCT	WO	PCT	PEN	Methods for the Synthesis of Unsymmetrical Cycloalkyl Substituted Xanthines	US2006/006838 02/27/06
029514.0067	ATL-008-PR	US	PRO	CLD	Provisional - Methods for the Synthesis of Unsymmetrical Cycloalkyl Substituted Xanthines	60/656,104 2/25/05

PATENT

REEL: 022075 FRAME: 0742

WM File No.	Seller File No.	City	Case Type	Status	Short Title	App. No. App Date
029514.0054	ATL-008-US	US	NAT	PEN	Utility - Methods for the Synthesis of Unsymmetrical Cycloalkyl Substituted Xanthines	11/362,390 10/13/06
029514.0026	ATL-009-PCT	WO	PCT	PEN	Derivatives of 8-Substituted Xanthines	US2006/06746 02/27/06
029514.0063	ATL-009-PR	US	PRO	CLD	Provisional - Derivatives of 8 - Substituted Xanthines	60/656,086 02/25/06
029514.0064	ATL-009-US	US	NAT	PEN	Utility - Derivatives of 8 - Substituted Xanthines	11/362,392 02/27/06
029514.0093	ATL-010-PCT	WO	PCT	PEN	Selective Antagonist of A2A Adenosine Receptors	PCT/US2007/016164 7/17/07
029514.0050	ATL-010-PR	US	PRO	CLD	Provisional 2 - Selective Antagonists A2A Adenosine Receptors	60/807,545 07/17/06
029514.0092	ATL-010-US	US	NAT	PEN	Selective Antagonists of A2A Adenosine Receptors	11/879,133 7/16/07
<del>029514.0056</del>	<del>ATL-011-PR</del>	<del>US</del>	<del>PRO</del>	<del>CLD</del>	<del>Provisional - New Compositions and Methods for the Treatment of Inflammation</del>	<del>60/504,439</del>
<del>029514.0066</del>	<del>ATL-011-US</del>	<del>US</del>	<del>NAT</del>	<del>PEN</del>	<del>Utility - New Compositions and Methods for the Treatment of Inflammation</del>	<del>61/497,280</del>
029514.0061	ATL-012-PR	US	PRO	CLD	Provisional - Methods for the Synthesis of Substituted Amino Uracils	60/711,422 08/26/05
029514.0062	ATL-012-US	US	NAT	PEN	Utility - Methods for the Synthesis of Substituted Amino Uracils	11/510,632 08/28/06
029514.0097	ATL-014-PCT	WO	PCT	PEN	Pyrrolo[3,2-D]Pyrimidines That Are Selective Antagonists of A2B Adenosine Receptors	US2007/019266 9/4/07
029514.0052	ATL-014-PR	US	PRO	CLD	Provisional - Selective Antagonists A2B Adenosine Receptors	60/824,316 09/01/06
029514.0096	ATL-014-US	US	NAT	PEN	PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS	11/897,678 8/31/07
<del>029514.0053</del>	<del>ATL-015-PR</del>	<del>US</del>	<del>PRO</del>	<del>CLD</del>	<del>Provisional - Antagonists of A2B Adenosine Receptors for Treatment of Inflammatory Bowel Disease</del>	<del>60/529,969</del>
<del>029514.0064</del>	<del>ATL-015-PR</del>	<del>US</del>	<del>PRO</del>	<del>CLD</del>	<del>Antagonists of A2B Adenosine Receptors for Treatment of Inflammatory Bowel Disease</del>	<del>60/878,619</del>

PATENT

REEL: 022075 FRAME: 0743

WM File No.	Seller File No.	Crty	Case Type	Status	Short Title	App. No. App Date
029514.0107	ATL-016-PCT	WO	PCT	PEN	Agonists of A2A Adenosine Receptors for Treating Recurrent Tumor Growth in the Liver Following Resection	US2008/060304 4/15/08
029514.0072	ATL-016-PR	US	PRO	CLD	Agonists of A2A Adenosine Receptors for Treating Recurrent Tumor Growth in the Liver Following Resection	60925736 4/23/07
029514.0106	ATL-016-US	US	NAT	PEN	Agonists of A2A Adenosine Receptors for Treating Recurrent Tumor Growth in the Liver Following Resection	12/102, 185 4/14/08
029514.0102	ATL-017-P1	US	PRO	PEN	SUBSTITUTED 4-{3-[6-AMINO-9-(3, 4-DIHYDROXY-TETRAHYDRO-FURAN-2-YL)-9H-PURIN-2-YL]-PROP-2-VINYLYL}-PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS	61/015,303 12/20/2007
029514.0103	ATL-018-P1	US	PRO	PEN	INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS	61/019, 912 1/09/2008
029514.0101	ATL-019-P1	US	PRO	PEN	SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES	61/014, 134 12/17/2007
029514.0109	ATL-021-P1	US	PRO	PEN	Substituted 8-[Carbonylamino -3-Pyridyl] Xanthines	61/046,568 4/24/08
029514.0105	ATL-022-PCT	WO	PCT	PEN	Adenosine Derivative Formulations for Medical Imaging	US2008/00549 1/16/2008
029514.0079	ATL-022-PR	US	PRO	EXP	Adenosine Derivative Formulations for Medical Imaging	60/885,489 1/18/07
029514.0104	ATL-022-US	US	NAT	PEN	Adenosine Derivative Formulations for Medical Imaging	12/014, 949 1/16/2008
029514.0113	ATL-023-P1	US	PRO	PEN	Alkoxy-Carbonyl-Amino-Alkyl-Adenosine Compounds and Derivatives Thereof as A2AR Agonists	61/075, 096 25299710 4/19/08
<del>029514.0083</del>	<del>ATL-7224-CA</del>	<del>SA</del>	<del>XP2</del>	<del>PEN</del>	<del>Methods for Preparing 2-Alkyladenosine Derivatives</del>	<del>200480020480X 4/10/06</del>
<del>029514.0084</del>	<del>ATL-7224-CN</del>	<del>CN</del>	<del>XP2</del>	<del>PEN</del>	<del>Methods for Preparing 2-Alkyladenosine Derivatives</del>	<del>0475274110 4/14/05</del>
<del>029514.0085</del>	<del>ATL-7224-EB</del>	<del>ER</del>	<del>XP2</del>	<del>PEN</del>	<del>Methods for Preparing 2-Alkyladenosine Derivatives</del>	<del>06112055.0 12/19/06</del>
<del>029514.0086</del>	<del>ATL-7224-HK</del>	<del>HK</del>	<del>XP2</del>	<del>PEN</del>	<del>Methods for Preparing 2-Alkyladenosine Derivatives</del>	<del>12/19/06</del>

PATENT

REEL: 022075 FRAME: 0744

WM File No.	Seller File No.	Ctry	Case Type	Status	Short Title	App. No. App Date
<del>029514.0082</del>	<del>ATL-7224-IN</del>	<del>IN</del>	<del>XP2</del>	<del>PEN</del>	<del>Methods for Preparing 2-Alkynyladenosine Derivatives</del>	<del>0780/DE/NR/2005 14/10/05</del>
<del>029514.0079</del>	<del>ATL-7224-IB</del>	<del>IB</del>	<del>XP2</del>	<del>PEN</del>	<del>Methods for Preparing 2-Alkynyladenosine Derivatives</del>	<del>2005-602222 4/24/05</del>
<del>029514.0088</del>	<del>ATL-7224-MX</del>	<del>MX</del>	<del>XP2</del>	<del>PEN</del>	<del>Methods for Preparing 2-Alkynyladenosine Derivatives</del>	<del>PAY/2005/07/2009 1/14/5/05</del>
029514.0080	ATL-7224-PR	US	PRO	CLD	Methods for Preparing 2-Alkynyladenosine Derivatives	60471643 5/19/03
029514.0081	ATL-7224-US	US	NAT	CLD	Methods for Preparing 2-Alkynyladenosine Derivatives	10848403 5/18/04
029514.0098	ATL-7224-US- CNT1	US	CONT	PEN	Methods for Preparing 2-Alkynyladenosine Derivatives	11/975,080 10/17/2007
029514.0082	ATL-7224-WO	WO	PCT	EXP	Methods for Preparing 2-Alkynyladenosine Derivatives	PCT/US2004/015783 5/19/04

PATENT

REEL: 022075 FRAME: 0745